Effects of CYP2C9 and CYP2C19 genetic polymorphisms on the pharmacokinetics and pharmacodynamics of gliclazide in healthy subjects
Arch Pharm Res. 2023 May;46(5):438-447. doi: 10.1007/s12272-023-01448-z. Epub 2023 Apr 25.ABSTRACTGliclazide metabolism is mediated by genetically polymorphic CYP2C9 and CYP2C19 enzymes. We investigated the effects of CYP2C9 and CYP2C19 genetic polymorphisms on the pharmacokinetics and pharmacodynamics of gliclazide. Twenty-seven Korean healthy volunteers were administered a single oral dose of gliclazide 80 mg. The plasma concentration of gliclazide was quantified for the pharmacokinetic analysis and plasma concentrations of glucose and insulin were measured as pharmacodynamic parameters. The pharmacokinetics of gliclazid...
Source: Archives of Pharmacal Research - April 25, 2023 Category: Drugs & Pharmacology Authors: Pureum Kang Chang-Keun Cho Choon-Gon Jang Seok-Yong Lee Yun Jeong Lee Chang-Ik Choi Jung-Woo Bae Source Type: research
Effects of CYP2C9 and CYP2C19 genetic polymorphisms on the pharmacokinetics and pharmacodynamics of gliclazide in healthy subjects
Arch Pharm Res. 2023 May;46(5):438-447. doi: 10.1007/s12272-023-01448-z. Epub 2023 Apr 25.ABSTRACTGliclazide metabolism is mediated by genetically polymorphic CYP2C9 and CYP2C19 enzymes. We investigated the effects of CYP2C9 and CYP2C19 genetic polymorphisms on the pharmacokinetics and pharmacodynamics of gliclazide. Twenty-seven Korean healthy volunteers were administered a single oral dose of gliclazide 80 mg. The plasma concentration of gliclazide was quantified for the pharmacokinetic analysis and plasma concentrations of glucose and insulin were measured as pharmacodynamic parameters. The pharmacokinetics of gliclazid...
Source: Archives of Pharmacal Research - April 25, 2023 Category: Drugs & Pharmacology Authors: Pureum Kang Chang-Keun Cho Choon-Gon Jang Seok-Yong Lee Yun Jeong Lee Chang-Ik Choi Jung-Woo Bae Source Type: research
Effects of CYP2C9 and CYP2C19 genetic polymorphisms on the pharmacokinetics and pharmacodynamics of gliclazide in healthy subjects
Arch Pharm Res. 2023 Apr 25. doi: 10.1007/s12272-023-01448-z. Online ahead of print.ABSTRACTGliclazide metabolism is mediated by genetically polymorphic CYP2C9 and CYP2C19 enzymes. We investigated the effects of CYP2C9 and CYP2C19 genetic polymorphisms on the pharmacokinetics and pharmacodynamics of gliclazide. Twenty-seven Korean healthy volunteers were administered a single oral dose of gliclazide 80 mg. The plasma concentration of gliclazide was quantified for the pharmacokinetic analysis and plasma concentrations of glucose and insulin were measured as pharmacodynamic parameters. The pharmacokinetics of gliclazide show...
Source: Archives of Pharmacal Research - April 25, 2023 Category: Drugs & Pharmacology Authors: Pureum Kang Chang-Keun Cho Choon-Gon Jang Seok-Yong Lee Yun Jeong Lee Chang-Ik Choi Jung-Woo Bae Source Type: research
Effects of CYP2C9 and CYP2C19 genetic polymorphisms on the pharmacokinetics and pharmacodynamics of gliclazide in healthy subjects
Arch Pharm Res. 2023 Apr 25. doi: 10.1007/s12272-023-01448-z. Online ahead of print.ABSTRACTGliclazide metabolism is mediated by genetically polymorphic CYP2C9 and CYP2C19 enzymes. We investigated the effects of CYP2C9 and CYP2C19 genetic polymorphisms on the pharmacokinetics and pharmacodynamics of gliclazide. Twenty-seven Korean healthy volunteers were administered a single oral dose of gliclazide 80 mg. The plasma concentration of gliclazide was quantified for the pharmacokinetic analysis and plasma concentrations of glucose and insulin were measured as pharmacodynamic parameters. The pharmacokinetics of gliclazide show...
Source: Archives of Pharmacal Research - April 25, 2023 Category: Drugs & Pharmacology Authors: Pureum Kang Chang-Keun Cho Choon-Gon Jang Seok-Yong Lee Yun Jeong Lee Chang-Ik Choi Jung-Woo Bae Source Type: research
Effects of CYP2C9 and CYP2C19 genetic polymorphisms on the pharmacokinetics and pharmacodynamics of gliclazide in healthy subjects
Arch Pharm Res. 2023 Apr 25. doi: 10.1007/s12272-023-01448-z. Online ahead of print.ABSTRACTGliclazide metabolism is mediated by genetically polymorphic CYP2C9 and CYP2C19 enzymes. We investigated the effects of CYP2C9 and CYP2C19 genetic polymorphisms on the pharmacokinetics and pharmacodynamics of gliclazide. Twenty-seven Korean healthy volunteers were administered a single oral dose of gliclazide 80 mg. The plasma concentration of gliclazide was quantified for the pharmacokinetic analysis and plasma concentrations of glucose and insulin were measured as pharmacodynamic parameters. The pharmacokinetics of gliclazide show...
Source: Archives of Pharmacal Research - April 25, 2023 Category: Drugs & Pharmacology Authors: Pureum Kang Chang-Keun Cho Choon-Gon Jang Seok-Yong Lee Yun Jeong Lee Chang-Ik Choi Jung-Woo Bae Source Type: research
Effects of CYP2C9 and CYP2C19 genetic polymorphisms on the pharmacokinetics and pharmacodynamics of gliclazide in healthy subjects
Arch Pharm Res. 2023 Apr 25. doi: 10.1007/s12272-023-01448-z. Online ahead of print.ABSTRACTGliclazide metabolism is mediated by genetically polymorphic CYP2C9 and CYP2C19 enzymes. We investigated the effects of CYP2C9 and CYP2C19 genetic polymorphisms on the pharmacokinetics and pharmacodynamics of gliclazide. Twenty-seven Korean healthy volunteers were administered a single oral dose of gliclazide 80 mg. The plasma concentration of gliclazide was quantified for the pharmacokinetic analysis and plasma concentrations of glucose and insulin were measured as pharmacodynamic parameters. The pharmacokinetics of gliclazide show...
Source: Archives of Pharmacal Research - April 25, 2023 Category: Drugs & Pharmacology Authors: Pureum Kang Chang-Keun Cho Choon-Gon Jang Seok-Yong Lee Yun Jeong Lee Chang-Ik Choi Jung-Woo Bae Source Type: research
Effects of CYP2C9 and CYP2C19 genetic polymorphisms on the pharmacokinetics and pharmacodynamics of gliclazide in healthy subjects
Arch Pharm Res. 2023 Apr 25. doi: 10.1007/s12272-023-01448-z. Online ahead of print.ABSTRACTGliclazide metabolism is mediated by genetically polymorphic CYP2C9 and CYP2C19 enzymes. We investigated the effects of CYP2C9 and CYP2C19 genetic polymorphisms on the pharmacokinetics and pharmacodynamics of gliclazide. Twenty-seven Korean healthy volunteers were administered a single oral dose of gliclazide 80 mg. The plasma concentration of gliclazide was quantified for the pharmacokinetic analysis and plasma concentrations of glucose and insulin were measured as pharmacodynamic parameters. The pharmacokinetics of gliclazide show...
Source: Archives of Pharmacal Research - April 25, 2023 Category: Drugs & Pharmacology Authors: Pureum Kang Chang-Keun Cho Choon-Gon Jang Seok-Yong Lee Yun Jeong Lee Chang-Ik Choi Jung-Woo Bae Source Type: research
Effects of CYP2C9 and CYP2C19 genetic polymorphisms on the pharmacokinetics and pharmacodynamics of gliclazide in healthy subjects
Arch Pharm Res. 2023 Apr 25. doi: 10.1007/s12272-023-01448-z. Online ahead of print.ABSTRACTGliclazide metabolism is mediated by genetically polymorphic CYP2C9 and CYP2C19 enzymes. We investigated the effects of CYP2C9 and CYP2C19 genetic polymorphisms on the pharmacokinetics and pharmacodynamics of gliclazide. Twenty-seven Korean healthy volunteers were administered a single oral dose of gliclazide 80 mg. The plasma concentration of gliclazide was quantified for the pharmacokinetic analysis and plasma concentrations of glucose and insulin were measured as pharmacodynamic parameters. The pharmacokinetics of gliclazide show...
Source: Archives of Pharmacal Research - April 25, 2023 Category: Drugs & Pharmacology Authors: Pureum Kang Chang-Keun Cho Choon-Gon Jang Seok-Yong Lee Yun Jeong Lee Chang-Ik Choi Jung-Woo Bae Source Type: research
Antibody drug conjugates as targeted cancer therapy: past development, present challenges and future opportunities
Arch Pharm Res. 2023 Apr 18. doi: 10.1007/s12272-023-01447-0. Online ahead of print.ABSTRACTAntibody drug conjugates (ADCs) are promising cancer therapeutics with minimal toxicity as compared to small cytotoxic molecules alone and have shown the evidence to overcome resistance against tumor and prevent relapse of cancer. The ADC has a potential to change the paradigm of cancer chemotherapeutic treatment. At present, 13 ADCs have been approved by USFDA for the treatment of various types of solid tumor and haematological malignancies. This review covers the three structural components of an ADC-antibody, linker, and cytotoxi...
Source: Archives of Pharmacal Research - April 18, 2023 Category: Drugs & Pharmacology Authors: Ritwik Maiti Bhumika Patel Nrupesh Patel Mehul Patel Alkesh Patel Nirav Dhanesha Source Type: research
Antibody drug conjugates as targeted cancer therapy: past development, present challenges and future opportunities
Arch Pharm Res. 2023 Apr 18. doi: 10.1007/s12272-023-01447-0. Online ahead of print.ABSTRACTAntibody drug conjugates (ADCs) are promising cancer therapeutics with minimal toxicity as compared to small cytotoxic molecules alone and have shown the evidence to overcome resistance against tumor and prevent relapse of cancer. The ADC has a potential to change the paradigm of cancer chemotherapeutic treatment. At present, 13 ADCs have been approved by USFDA for the treatment of various types of solid tumor and haematological malignancies. This review covers the three structural components of an ADC-antibody, linker, and cytotoxi...
Source: Archives of Pharmacal Research - April 18, 2023 Category: Drugs & Pharmacology Authors: Ritwik Maiti Bhumika Patel Nrupesh Patel Mehul Patel Alkesh Patel Nirav Dhanesha Source Type: research
Antibody drug conjugates as targeted cancer therapy: past development, present challenges and future opportunities
Arch Pharm Res. 2023 Apr 18. doi: 10.1007/s12272-023-01447-0. Online ahead of print.ABSTRACTAntibody drug conjugates (ADCs) are promising cancer therapeutics with minimal toxicity as compared to small cytotoxic molecules alone and have shown the evidence to overcome resistance against tumor and prevent relapse of cancer. The ADC has a potential to change the paradigm of cancer chemotherapeutic treatment. At present, 13 ADCs have been approved by USFDA for the treatment of various types of solid tumor and haematological malignancies. This review covers the three structural components of an ADC-antibody, linker, and cytotoxi...
Source: Archives of Pharmacal Research - April 18, 2023 Category: Drugs & Pharmacology Authors: Ritwik Maiti Bhumika Patel Nrupesh Patel Mehul Patel Alkesh Patel Nirav Dhanesha Source Type: research
Antibody drug conjugates as targeted cancer therapy: past development, present challenges and future opportunities
Arch Pharm Res. 2023 Apr 18. doi: 10.1007/s12272-023-01447-0. Online ahead of print.ABSTRACTAntibody drug conjugates (ADCs) are promising cancer therapeutics with minimal toxicity as compared to small cytotoxic molecules alone and have shown the evidence to overcome resistance against tumor and prevent relapse of cancer. The ADC has a potential to change the paradigm of cancer chemotherapeutic treatment. At present, 13 ADCs have been approved by USFDA for the treatment of various types of solid tumor and haematological malignancies. This review covers the three structural components of an ADC-antibody, linker, and cytotoxi...
Source: Archives of Pharmacal Research - April 18, 2023 Category: Drugs & Pharmacology Authors: Ritwik Maiti Bhumika Patel Nrupesh Patel Mehul Patel Alkesh Patel Nirav Dhanesha Source Type: research
Antibody drug conjugates as targeted cancer therapy: past development, present challenges and future opportunities
Arch Pharm Res. 2023 Apr 18. doi: 10.1007/s12272-023-01447-0. Online ahead of print.ABSTRACTAntibody drug conjugates (ADCs) are promising cancer therapeutics with minimal toxicity as compared to small cytotoxic molecules alone and have shown the evidence to overcome resistance against tumor and prevent relapse of cancer. The ADC has a potential to change the paradigm of cancer chemotherapeutic treatment. At present, 13 ADCs have been approved by USFDA for the treatment of various types of solid tumor and haematological malignancies. This review covers the three structural components of an ADC-antibody, linker, and cytotoxi...
Source: Archives of Pharmacal Research - April 18, 2023 Category: Drugs & Pharmacology Authors: Ritwik Maiti Bhumika Patel Nrupesh Patel Mehul Patel Alkesh Patel Nirav Dhanesha Source Type: research
Antibody drug conjugates as targeted cancer therapy: past development, present challenges and future opportunities
Arch Pharm Res. 2023 Apr 18. doi: 10.1007/s12272-023-01447-0. Online ahead of print.ABSTRACTAntibody drug conjugates (ADCs) are promising cancer therapeutics with minimal toxicity as compared to small cytotoxic molecules alone and have shown the evidence to overcome resistance against tumor and prevent relapse of cancer. The ADC has a potential to change the paradigm of cancer chemotherapeutic treatment. At present, 13 ADCs have been approved by USFDA for the treatment of various types of solid tumor and haematological malignancies. This review covers the three structural components of an ADC-antibody, linker, and cytotoxi...
Source: Archives of Pharmacal Research - April 18, 2023 Category: Drugs & Pharmacology Authors: Ritwik Maiti Bhumika Patel Nrupesh Patel Mehul Patel Alkesh Patel Nirav Dhanesha Source Type: research
Phytochemistry and pharmacology of natural prenylated flavonoids
Arch Pharm Res. 2023 Apr 14:1-66. doi: 10.1007/s12272-023-01443-4. Online ahead of print.ABSTRACTPrenylated flavonoids are a special kind of flavonoid derivative possessing one or more prenyl groups in the parent nucleus of the flavonoid. The presence of the prenyl side chain enriched the structural diversity of flavonoids and increased their bioactivity and bioavailability. Prenylated flavonoids show a wide range of biological activities, such as anti-cancer, anti-inflammatory, neuroprotective, anti-diabetic, anti-obesity, cardioprotective effects, and anti-osteoclastogenic activities. In recent years, many compounds with...
Source: Archives of Pharmacal Research - April 13, 2023 Category: Drugs & Pharmacology Authors: Hua-Wei Lv Qiao-Liang Wang Meng Luo Meng-Di Zhu Hui-Min Liang Wen-Jing Li Hai Cai Zhong-Bo Zhou Hong Wang Sheng-Qiang Tong Xing-Nuo Li Source Type: research
